Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VHGI is looking interesting, worth looking over
from what im hearing it looks like this stock is gonna explode real soon
i was out of this jail hell for 3 days now im back in.....:(
I HAVE NO IDEA WHAT I WAS BANNED FOR!
i think we are sure to jump here
ya thanks for the charts
today wasn't the greatest but iv heard some good news some i think we will begin to pick up
AMCG is looking pretty hot give it a look
check out SNWT its doing pretty good
tomorrow is gonna be good i think really exited for the week
cant wait till tomorrow its gonna be great anyone got and new news
stocks doing good anyone know about new stuff comeing up?
looking forward to this weeks opening
this stock is awesome been really good to me so far no telling how far we could go
Great close today wow this is awesome hoping for a green Monday
high hopes for tomorrow as well
good to see some green looks like we had good today
check out SNWT its doing great
SNWT did great today,look into it
was great to see some movement today
NICE GOOD DAY TODAY
can't wait to see some green here won't be long
looks like a good company
SNWT looks good check it out
company looks solid hoping for some green in the near future i have high hopes
SNDZ check it out
The company look interesting gonna check it out
JCOF looking good
JCOF
posted January 28, 2010 13:30
Javaluation Manufacturing Process
Javalution Coffee Company owns its own coffee roasting operation located in Miami, Florida. Our roasting facility operates under the corporate name CLR Roasters which is a wholly owned subsidiary of Javalution Coffee Company. Our roasting operations are housed in an 18,000 square foot facility with ample roasting and packaging capabilities to grow our operations well into the foreseeable future. Although our plant is currently operating at 40% capacity we have invested in additional equipment that will allow us to double our production capacity. In the event of rapid growth and demand of our products our facility is specifically designed so the production capacity can be rapidly expanded as our business warrants increased throughput. In addition to the production, roasting and packaging of the JavaFit Brand of coffee CLR Roasters provides private label coffee roasting to various clients and CLR Roasters also markets its Café La Rica brand of espresso to various national chain retailers. Javalution Coffee Company is proud to control 100% of its production of JavaFit within its own roasting operations. This allows us to guarantee that JavaFit is produced utilizing only the finest coffee beans from the finest growing regions in the world. We have complete control of the quality of the roast, the blend, the management of the mixing of the neutraceuticals and vitamins into our coffee and the packaging process. Every JavaFit batch is coded for tracking purposes and each batch is cupped to assure that each batch meets our high standards for roast, blend, grind and taste.
JCOF looks interesting check it out
hopefully some green will surface soon
LAS VEGAS, Jan 19, 2010 (GlobeNewswire via COMTEX) -- The aging baby boomers and a national obesity crisis have contributed to an enormous frequency of diabetes in the American population. For many, sticking a needle in their fingers is the only way to know if their blood sugar levels are normal. It indeed seems a primitive practice in a world where kids now have games and toys where they move objects only with their minds.
To the rescue of this group and others looking for a method beyond the oft-used, needle-through-the-finger technique is Echo Therapeutics (OTCBB:ECTE), which is focused on transdermal continuous glucose monitoring systems for people with diabetes and advanced topical reformulations of FDA-approved specialty pharmaceuticals.
Simply put, the company has invented a process called Symphony that negates the need in some instances for the venerable needle by prepping the skin to allow for a wireless reading of the glucose level. Echo's method used to prep the skin for Symphony is called Prelude(TM) SkinPrep, a novel, needle-free platform technology that increases skin permeability. It can be used for drug delivery as well, opening doors to a whole new and potentially broad category of uses.
From our vantage, Echo's technology looks like a better mousetrap idea long overdue with a large class of potential patients. Moreover, the drug delivery system appears to be a game-changer if adopted by larger companies looking for a different way to deliver drugs into patients without a needle.
Prelude certainly garners additional credibility with a promising deal with Ferndale Pharmaceuticals signed already. Echo has inked a $15 million agreement, giving Ferndale a license to develop, market and sell Prelude for enhanced delivery of Ferndale's topical lidocaine product. Echo received $750,000 up-front and will receive $750,000 upon FDA approval, as well as $12.5 million in milestones and guaranteed minimum royalty payments. Echo will also receive a double-digit royalty on net sales of the product.
FRANKLIN, Mass., Jan 11, 2010 /PRNewswire via COMTEX/ -- Echo Therapeutics, Inc. (OTC Bulletin Board : ECTE), a company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, announced today that the Company has completed the product development work for its Prelude SkinPrep System and now has the commercially ready product to be used in final clinical trials.
Echo anticipates that no further changes will be made to the Prelude SkinPrep System and that the current device will be the one used for sale, subject to FDA market clearance of the product. The final Prelude device replaces the prototype device used in earlier clinical trials and will be tested in the near-term in a study using LMX4 lidocaine cream which should form the basis for a 510-k filing with Ferndale Pharma Group for the enhanced delivery of lidocaine. The Company believes that the addressable market for enhanced, fast acting topical lidocaine exceeds $1 billion.
"The completion of the product development work on our Prelude SkinPrep System, our skin preparation platform technology used for both transdermal drug delivery and skin preparation prior to the application of the Symphony tCGM glucose biosensor represents one of the most important milestone events in the Company's history," stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "We are now prepared to complete our clinical validation and begin commercialization efforts in enhanced topical lidocaine delivery. This next generation skin preparation device incorporates substantial improvements beyond the prototype used in earlier studies. We anticipate testing Prelude with LMX4 anesthetic cream for enhanced local dermal anesthesia in the near-term and subsequently seeking 510-k market clearance from the FDA."
The Company also anticipates that the completed Prelude will be tested in the near future with its recently completed one-piece, cost-effective, single-use Symphony tCGM glucose biosensor in patients with diabetes and critically ill patients who require aggressive glucose monitoring. Prelude incorporates Echo's patented skin permeation control feedback technology into a comfortable, wireless, hand-held device used to prepare a small area of the skin for the non-invasive, biosensor and monitoring components of its Symphony tCGM system or for transdermal drug delivery.
About Echo Therapeutics
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of the Symphony tCGM System and Prelude SkinPrep System, the failure of future development and preliminary marketing efforts related to the Symphony tCGM System and Prelude SkinPrep System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM System and Prelude SkinPrep System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to the Symphony tCGM System and the Prelude SkinPrep System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.
Wireless power / wireless charging is the latest buzz technology gaining buzz out of CES. KCMH just announced on January 5th that a letter of intent was signed to incubate a wireless power company. This is a big step for KCMH to sign an LOI to get involved in the burgeoning wireless power industry!
Management:
Donald Klein, CEO, President and Chairman of the Board
Mr. Klein brings a reputable and experienced background of entrepreneurial success to the Company and is responsible for its private equity and publicly traded investment businesses. He is Chairman of the board of directors and founder of KCM Holdings Corp.
Mr. Klein's diverse investment and management acumen lends itself to the credibility and strength of the KCM Holdings Corporation business strategy. His experience ranges from building multi million-dollar producing insurance agencies where he also held positions as managing partner and director of Insurance Services at Southwest Texas Capital, to trading for hedge funds and proprietary capital for a number of Wall Street Firms. Mr. Klein understands the necessity of building management teams for successful exponential growth and financial returns. Mr. Klein received his M.B.A. from Southern California University for Professional Studies.
Ed Kang, Chief Operating Officer
Mr. Kang has many years of entrepreneurial and management experience in strategic business development on both local and international scales. In 1997 he founded media firm, K2M, with Donald Klein in South Florida. Mr. Kang was able to negotiate a strategic alliance with The International Museum of Cartoon Art, which at the time was the world's largest cartoon strip and animation museum. The multi-national Latin entertainment conglomerate Caiman Entertainment later acquired K2M. While at Caiman Entertainment, Mr. Kang served as a creative director in intellectual properties development, managing brand identities for television and recording artists, including Chi Chi Peralta who was nominated for a Latin Grammy awards.
During the same time, Mr. Kang provided branding and design work for Warner/Chappell Music Publishing, which at that time was a division of AOL Time Warner, providing support for national marketing strategies to major advertising agencies and commercial brand managers.
Chad Lefevre, Senior Director of Strategic Development
Mr. Lefevre is the former Director of Blue Energy, a marketing and communications company whose assets where acquired by KCM Holdings in early 2008. He has co-developed KCM business development strategies, stemming from his experience as an entrepreneur, business development and communications expert, and business philosopher.
Prior to managing multiple real estate pr marketing operations contributing to over $100 million in sales, he provided 12 years of business development and strategic operational consultancy services in the energy sector, and at various levels of government. He developed enterprise sales best practices and strategies to open new product markets in the oil and gas industry for Telco giant, Bell. His teaching experience includes serving as an instructor for a joint University of Calgary faculty of Communications and Haskayne School of Business program in the area of business communications.
KCMH looking ready for a turn around take a look
KCMH will do good in the long run i think
ECTE is going good today check it out
http://investorshub.advfn.com/boards/board.aspx?board_id=2898
ECTE looks like it had a good day today
stock looks interesting and it had a good day today,something to get involved in,adding to ticker